We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
76
CALL
Celldex Therapeutics
CLDX
$2.99B
$7.01M 0.31%
400,000
+336,200
+527% +$6.05M
BTAI icon
77
CALL
BioXcel Therapeutics
BTAI
$24.9M
$6.93M 0.31%
9,375
– –
IMTX icon
78
Immatics
IMTX
$1.18B
$6.88M 0.3%
638,094
– –
ALNY icon
79
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
$6.5M 0.29%
50,000
– –
MRNA icon
80
Moderna
MRNA
$21.8B
$6.48M 0.29%
+62,059
New +$6.28M
OCUL icon
81
CALL
Ocular Therapeutix
OCUL
$1.79B
$6.46M 0.28%
+312,100
New +$4.64M
TCDA
82
DELISTED
Tricida, Inc. Common Stock
TCDA
$6.05M 0.27%
858,908
+835,715
+3,603% +$6.41M
SLDB icon
83
Solid Biosciences
SLDB
$794M
$5.97M 0.26%
52,534
– –
CMRX
84
DELISTED
Chimerix, Inc.
CMRX
$5.95M 0.26%
1,232,513
-131,531
-10% -$477K
SBBP
85
DELISTED
Strongbridge Biopharma plc.
SBBP
$5.93M 0.26%
2,440,028
-922,214
-27% -$2.22M
SAGE
86
DELISTED
Sage Therapeutics
SAGE
$5.72M 0.25%
66,151
-50,000
-43% -$3.69M
SRRK icon
87
Scholar Rock
SRRK
$5.67B
$5.68M 0.25%
+117,059
New +$4.25M
AGIO icon
88
CALL
Agios Pharmaceuticals
AGIO
$1.79B
$5.42M 0.24%
+125,000
New +$4.94M
SNCE
89
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$5.36M 0.24%
+25,250
New +$5.25M
XFOR icon
90
X4 Pharmaceuticals
XFOR
$375M
$5.31M 0.23%
27,547
+3,391
+14% +$666K
TGTX icon
91
PUT
TG Therapeutics
TGTX
$7.96B
$5.2M 0.23%
+100,000
New +$3.38M
FULC icon
92
Fulcrum Therapeutics
FULC
$273M
$5.13M 0.23%
+437,700
New +$4.95M
SRRA
93
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.11M 0.23%
318,890
+5,000
+2% +$69.4K
ONCT
94
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$5.05M 0.22%
+51,516
New +$3.26M
CCCC icon
95
C4 Therapeutics
CCCC
$385M
$5.02M 0.22%
+151,500
New +$4.39M
VSTM icon
96
Verastem
VSTM
$510M
$4.8M 0.21%
187,883
+70,106
+60% +$1.41M
QNCX icon
97
PUT
Quince Therapeutics
QNCX
$22.9M
$4.72M 0.21%
850
+835
+5,567% +$7.4M
CYTK icon
98
Cytokinetics
CYTK
$10.5B
$4.72M 0.21%
227,000
+172,000
+313% +$3.14M
BLUE
99
CALL
DELISTED
bluebird bio
BLUE
$4.59M 0.2%
+8,199
New +$5.2M
TVRD
100
CALL
Tvardi Therapeutics
TVRD
$19.7M
$4.57M 0.2%
8,381
+6,770
+420% +$3.55M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.